Cavernous Sinus Thrombosis

Cavernous Sinus Thrombosis
Outside Resources
Radiopaedia	https://radiopaedia.org/articles/cavernous-sinus-thrombosis

1. Cavernous Sinus Thrombosis

Overview

Cavernous sinus thrombosis (CST) is a rare but life-threatening condition involving thrombosis and often septic inflammation of the cavernous sinus. The condition most commonly arises from infections of the paranasal sinuses, orbit, or central face ("danger triangle"), with Staphylococcus aureus as the predominant pathogen (60-70% of cases).

Despite advances in antimicrobial therapy, CST remains associated with significant morbidity and mortality. In the pre-antibiotic era, mortality exceeded 80-100%; contemporary mortality with aggressive treatment is now 8-15%, and as low as 3.3% when anticoagulation is utilized. Permanent neurological sequelae, particularly cranial nerve deficits and visual impairment, occur in 25-32% of survivors.

The condition is more common in young adults and has no significant gender predilection. Early recognition and aggressive treatment with antibiotics, anticoagulation, and surgical source control are essential for optimal outcomes.

History

The first clinical description of cavernous sinus thrombosis is attributed to Bright in 1831. Duncan characterized the classic clinical syndrome in 1821, describing the association with facial infection and orbital symptoms. The term "cavernous sinus" was introduced by Ridley in 1695 based on the trabeculated, "cavernous" appearance of the venous channel.

Prior to antibiotics, CST was uniformly fatal. The introduction of sulfonamides in the 1930s and penicillin in the 1940s dramatically improved survival. Eagleton established the classic clinical criteria for diagnosis in 1925-1926, which remained the standard until modern imaging became available. CT and MRI have revolutionized diagnosis, allowing earlier detection and treatment.

Epidemiology

Cavernous sinus thrombosis is rare, with an estimated incidence of 2-4 cases per million people annually.

Demographics:

• More common in young adults (median age 20-40 years)
• No significant gender predilection
• May occur in children (8% mortality in pediatric series)

Pathophysiology

Relevant Anatomy

The cavernous sinuses are paired, trabeculated venous channels located on either side of the sella turcica. Each sinus measures approximately 2 cm in length and 1 cm in width.

Contents of the cavernous sinus:

• Internal carotid artery: Passes through center of sinus with surrounding sympathetic plexus
• Cranial nerve VI (abducens): Passes through sinus, most vulnerable to injury due to medial location
• Cranial nerves III (oculomotor), IV (trochlear), V1 (ophthalmic), V2 (maxillary): Travel in lateral wall

Venous communications:

• Superior ophthalmic vein: Primary drainage from orbit, lacks valves
• Inferior ophthalmic vein: Drains into cavernous sinus or pterygoid plexus
• Sphenoparietal sinus: Connects to anterior aspect
• Superficial middle cerebral vein: Drains cerebral cortex
• Intercavernous sinuses: Connect the paired cavernous sinuses, allowing bilateral spread
• Superior and inferior petrosal sinuses: Provide posterior drainage

Adjacent structures:

• Pituitary gland (medially)
• Temporal lobe (superiorly)
• Meckel's cave with trigeminal ganglion (posterolaterally)
• Sphenoid sinus (inferiorly)

The valveless nature of the facial veins and ophthalmic veins allows retrograde flow of infected material into the cavernous sinus.

Disease Etiology

Sources of infection:

• Paranasal sinusitis: 30% of cases (may be higher in some populations - up to 93% in one series had sphenoid involvement)
  • Sphenoid and ethmoid sinusitis predominate
• Facial infections: Furuncles, carbuncles in the "danger triangle" of the face
• Orbital/periorbital infections: Orbital cellulitis, preseptal cellulitis
• Dental infections: Particularly maxillary teeth
• Otitis media/mastoiditis: Via petrosal sinuses
• Pharyngitis/tonsillitis: Less common

Microbiology:

Pathogen	Frequency	Notes
Staphylococcus aureus	60-70%	Most common; MRSA increasingly common (50% in one series)
Streptococcus species	~20%	S. pneumoniae, Group A Strep, viridans streptococci
Oral anaerobes	5-10%	Bacteroides, Peptostreptococcus, Fusobacterium (odontogenic)
Gram-negative bacilli	5-10%	Proteus, Haemophilus, Pseudomonas (sinusitis-associated)
Fungi	Rare	Aspergillus, Mucorales (immunocompromised only)
Polymicrobial	5-10%	Multiple organisms isolated

Blood cultures are positive in approximately 70% of cases.

Pathogenic mechanisms: 1. Septic emboli travel via valveless veins (ophthalmic, facial) 2. Bacteria seed trabeculated sinus 3. Inflammatory response causes thrombosis 4. Thrombophlebitis extends via intercavernous sinuses to contralateral side

  * Bilateral disease occurs in 30-40% of cases
  * Spread typically occurs within 24-48 hours of initial presentation

5. Cranial nerve dysfunction from compression and ischemia 6. Potential extension to meninges and brain parenchyma

Diagnosis

Patient History

Symptoms typically develop 5-10 days after primary infection. Classic presentation includes:

• Headache: Severe, retro-orbital or frontal (>90%)
• Fever: High-grade, often with rigors (>90%)
• Periorbital/facial swelling: Progressive, may become bilateral
• Visual symptoms: Diplopia, vision loss, photophobia
• Facial numbness: V1/V2 distribution
• History of recent infection: Sinusitis, facial boil, dental procedure

Red flags:

• Bilateral eye involvement (suggests contralateral extension)
• Altered mental status (meningitis or cerebral involvement)
• Rapid progression of symptoms
• Relative afferent pupillary defect (RAPD) - poor prognostic sign

Physical Examination

Classic findings (Eagleton criteria):

Eagleton's original 1925 criteria included: 1. Known site of infection 2. Septicemia (positive blood cultures) 3. Early signs of venous congestion (retinal vein fullness, proptosis, exophthalmos) 4. Ocular nerve palsies (CN III, IV, V, VI involvement) 5. Abscess or phlebitis contiguous to cavernous sinus 6. Signs of intracranial infection (headache, stiff neck, obtundation)

Modern examination findings:

• Proptosis (often bilateral in advanced disease)
• Chemosis and periorbital edema
• External ophthalmoplegia (CN III, IV, VI involvement)
• Visual loss (papilledema, retinal hemorrhages, central retinal artery occlusion)
• Sensory loss in V1/V2 distribution
• Fever and signs of systemic toxicity
• Horner syndrome (sympathetic plexus involvement)
• Relative afferent pupillary defect (RAPD) - critical prognostic finding

Progression:

• Unilateral findings initially (median 5-10 days after primary infection)
• Contralateral involvement within 24-48 hours via intercavernous sinuses
• Bilateral involvement present in 30-40% at diagnosis

Laboratory Tests

• Blood cultures: Positive in 70% of cases; obtain multiple sets before antibiotics
• Complete blood count: Leukocytosis with left shift
• Inflammatory markers: Elevated ESR, CRP, procalcitonin
• Glucose: Hyperglycemia is a relative contraindication to anticoagulation
• Coagulation studies: PT, PTT, fibrinogen, D-dimer
• Lumbar puncture: If meningitis suspected
  • CSF typically shows pleocytosis, elevated protein
  • Obtain after imaging to rule out mass effect
• Culture of primary site: Wound, sinus aspirate if accessible

Imaging

Critical point: Contrast-enhanced imaging is 100% sensitive for detecting CST, while non-contrast imaging is 0% sensitive.

Contrast-enhanced MRI (gold standard):

• High sensitivity (>95%) for early detection
• Superior to CT for detecting early thrombosis
• Findings:
  • Expansion of cavernous sinus
  • Filling defects within sinus (thrombus)
  • Absent or diminished flow void in internal carotid artery (if involved)
  • Lateral bulging of cavernous sinus wall
  • Proptosis and orbital fat stranding
  • Associated meningeal enhancement (if meningitis present)

MR venography (MRV):

• Confirms absent or diminished flow in cavernous sinus
• Evaluates extent of venous thrombosis
• Important: Non-contrast time-of-flight MRV is 0% sensitive - contrast required

Contrast-enhanced CT:

• More readily available than MRI
• Delayed phase imaging recommended in ED setting when MRI unavailable
• Findings:
  • Filling defects in cavernous sinus
  • Increased sinus size
  • Bulging lateral wall
  • Orbital findings (proptosis, fat stranding)
  • Paranasal sinus opacification (source)

Empty delta sign: Filling defect surrounded by contrast-enhancing dura; pathognomonic for venous sinus thrombosis.

Differential Diagnosis

• Orbital cellulitis without CST - most important differential
• Orbital apex syndrome (other etiologies)
• Tolosa-Hunt syndrome (idiopathic granulomatous inflammation)
• Mucormycosis or invasive fungal sinusitis
• Carotid-cavernous fistula
• Meningioma of cavernous sinus
• Pituitary apoplexy
• Aseptic cavernous sinus thrombosis (dehydration, hypercoagulable states)
• Orbital pseudotumor

Management

Medical Management

Antibiotic therapy is the cornerstone of treatment and must be initiated immediately:

Empiric regimens (designed to cover Staphylococcus including MRSA, Streptococcus species, and anaerobes):

• Vancomycin 15-20 mg/kg IV q8-12h (achieve trough 15-20 mcg/mL) PLUS
• Ceftriaxone 2 g IV q12h (or cefepime 2 g IV q8h for better CNS penetration) PLUS
• Metronidazole 500 mg IV q6-8h (for anaerobic coverage if odontogenic or mixed source)

Duration: Prolonged course, typically 3-6 weeks IV therapy minimum, individualized based on clinical response and source control.

Anticoagulation - Strong Evidence for Benefit

2024/2025 Meta-Analysis Data (strongest evidence to date):

Outcome	With Anticoagulation	Without Anticoagulation	Significance
Mortality	3.3%	18%	p = 0.022
Adjusted OR for mortality	0.067 (95% CI: 0.009-0.475)
Neurological morbidity	31%	61%	Significant benefit

Recommended regimen:

• Initial: Unfractionated heparin or LMWH
  • UFH: 5,000-10,000 units bolus, then 1,000-2,000 units/hour infusion
  • LMWH (enoxaparin): 1 mg/kg SC q12h
• Duration: Typically 3 months (one-third of patients in meta-analysis); individualize based on response
• Transition: Warfarin or DOAC after acute phase stabilization

Contraindications/Cautions:

• Hyperglycemia: Relative contraindication - careful consideration required
• Postoperative period: May be contraindicated in septic CST immediately after surgery due to hemorrhage risk
• Mycotic aneurysm (relative)
• Active intracranial hemorrhage

Note: No prospective RCTs exist; however, the 2024 individual patient data meta-analysis of 110 patients provides the strongest evidence to date.

Corticosteroids:

• Evidence limited; not routinely recommended
• May be considered for significant cranial nerve dysfunction or vision-threatening situations
• If used: dexamethasone 4-10 mg IV q6h

Surgical Management

Primary source control is absolutely essential - 81.5% of patients in the 2025 series underwent surgical intervention:

• Drainage of paranasal sinus abscess (endoscopic sinus surgery - ESS preferred)
• Incision and drainage of facial abscess/furuncle (including "danger triangle" lesions)
• Drainage of orbital abscess
• Extraction of infected teeth (coordination with oral surgery)
• Timing: Source control should be performed concurrently with initiation of antibiotics

Direct sinus thrombectomy: Rarely performed; of historical interest only and not recommended

Outcomes

Complications

Neurological:

• Cranial nerve palsies: Most common neurological sequela
  • CN VI (abducens): Most vulnerable due to medial location in sinus
  • CN III (oculomotor) and CN IV (trochlear): Lateral wall involvement
  • CN V (trigeminal): Ophthalmic (V1) and maxillary (V2) divisions
  • 2025 study: 31.8% had persistent EOM limitation
  • 2001 review: 17% had oculomotor weakness
• Vision loss:
  • 2025 study: 16.7% had no light perception vision
  • 2001 review: 17% had blindness
  • Causes: Central retinal artery occlusion, optic neuropathy, cortical blindness
• Stroke: Caused by ICA thrombosis or vasospasm
• Brain abscess: From hematogenous spread
• Meningitis/meningoencephalitis: From direct extension
• Subdural empyema: Potentially fatal complication
• Pituitary insufficiency: From compression or ischemia

Systemic:

• Septic shock
• Disseminated intravascular coagulation (DIC)
• Pulmonary septic emboli
• Multiple organ failure

Vascular:

• Mycotic aneurysm of internal carotid artery
• Carotid-cavernous fistula (post-thrombotic)
• Cerebral venous infarction
• Extension to other venous sinuses

Prognosis

Mortality - Contemporary Data:

Era/Study	Mortality	Notes
Pre-antibiotic era	80-100%	Uniformly fatal
2001 review (Ebright)	30%	Historical series
2015 pediatric review	8% (4/52)	Improved pediatric outcomes
2018 Dutch series	8.3% (1/12)	Contemporary management
2025 multicenter study	11.1%	Modern comprehensive care
With anticoagulation	3.3%	2024 meta-analysis
Without anticoagulation	18%	2024 meta-analysis

Contemporary mortality is 8-15%, with rates as low as 3.3% when anticoagulation is used.

Long-term sequelae (improving with modern management):

• Residual ophthalmoplegia: 25-32%
• Visual impairment or permanent blindness: 15-20%
• Pituitary dysfunction requiring hormone replacement: Rare
• Chronic headache/post-thrombotic syndrome

Prognostic factors:

Favorable	Poor
Early diagnosis (<7 days symptoms)	RAPD at presentation (37.5% mortality vs. 0%, p < 0.01)
Unilateral disease at presentation	Bilateral involvement
Good response to antibiotics (3-5 days)	Delayed treatment (>7-10 days)
Use of anticoagulation	Intracranial complications (meningitis, abscess)
Adequate source control (81.5% had surgery)	Septic shock requiring vasopressors
Younger age, no immunocompromise	Immunocompromise (diabetes, HIV, malignancy)
Normal glucose	Hyperglycemia

See Also

• Orbital Cellulitis - differential diagnosis and related condition
• Acute Mastoiditis - potential source via petrosal sinuses
• Paranasal Sinusitis - common source of infection
• Sigmoid Sinus Thrombosis - related venous sinus thrombosis